Rangaprasad Sarangarajan

This inventor holds 30 USPTO granted patents and 45 published patent applications, plus 6 CIPO patents and 12 EPO patents, primarily in Cancer Treatment. Top assignees: Berg LLC, Bpgbio, Inc., The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rangaprasad Sarangarajan. Retrieved from https://idiyas.com/inventor/rangaprasad-sarangarajan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 45)

% Patents Active = 90.0

CIPO Patents = 6 (Patent Applications = 21)

EPO Patents = 12 (Patent Applications = 31)

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 85(Granted Patents)

Location History:

Rutland, MA (US) (2015)
Boylston, MA (US) (2016 - 2023)

Company Filing History:

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

patents

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

Areas of Expertise:

Coenzyme Q10

Cancer Treatment

Cell-Based Assays

Epidermolysis Bullosa

Prostate Cancer

Temozolomide

Drug-Induced Toxicity

Metabolic Syndrome

Heat Shock Protein

Biochemical Recurrence

Tumor Prevention

Cardiotoxic Agents

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12691081 - Methods for the treatment of cancer using coenzyme Q10 combination therapies (2026-07-28),

2. 12653776 - Methods of treatment of cancer by continuous infusion of coenzyme Q10 (2026-06-16),

3. 12616666 - Coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa (2026-05-05),

4. 12437835 - Interrogatory cell-based assays and uses thereof (2025-10-07),

5. 12320812 - Markers for the diagnosis of biochemical recurrence in prostate cancer (2025-06-03),

6. 12303471 - Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 (2025-05-20),

7. 11694765 - Interrogatory cell-based assays for identifying drug-induced toxicity markers (2023-07-04),

8. 11456054 - Interrogatory cell-based assays and uses thereof (2022-09-27),

9. 11452699 - Method of treating or preventing tumors of the central nervous system (2022-09-27),

10. 11419830 - Use of coenzyme Q10 formulations in the treatment and prevention of epidermolysis bullosa (2022-08-23),

11. 11298313 - Methods of treatment of cancer by continuous infusion of coenzyme Q10 (2022-04-12),

12. 11224641 - Enolase 1 (ENO1) compositions and uses thereof (2022-01-18),

13. 11209422 - Methods and kits for detection of coenzyme Q10 (2021-12-28),

14. 11001891 - Methods for treating Parkinson's disease (2021-05-11),

15. 10933032 - Methods for the treatment of cancer using coenzyme Q10 combination therapies (2021-03-02),

Title: **Rangaprasad Sarangarajan: Innovator in Drug Toxicity and Disease Modeling**

Introduction

Rangaprasad Sarangarajan, based in Boylston, MA, is a prominent inventor with an impressive portfolio of 24 patents to his name. His work primarily focuses on the field of drug toxicity and disease modeling, showcasing his contributions to advancing medical science and pharmaceuticals.

Latest Patents

Among his latest innovations, Sarangarajan has developed a groundbreaking platform technology for analyzing drug-induced toxicity conditions. One of his patents is titled "Interrogatory cell-based assays for identifying drug-induced toxicity markers." This invention focuses on analyzing conditions such as cardiotoxicity through model building. Another notable patent is "Interrogatory cell-based assays and uses thereof," which describes a similar platform technology aimed at analyzing biological systems or processes, including disease conditions like cancer.

Career Highlights

Rangarprasad is currently employed at Berg LLC, a company dedicated to pioneering scientific advancements in human health. His inventive approach and expertise have greatly contributed to the company's mission of transforming the way diseases are understood and treated.

Collaborations

Throughout his career, Sarangarajan has collaborated with esteemed colleagues such as Niven Rajin Narain and Vivek Kannoth Vishnudas. These partnerships highlight the collaborative spirit within the scientific community, fostering an environment where groundbreaking discoveries can take place.

Conclusion

Rangaprasad Sarangarajan stands out as a key figure in the field of innovation, particularly in drug toxicity and disease modeling. His extensive patent portfolio not only underscores his expertise but also his commitment to enhancing healthcare through scientific innovation.

Profile summary based on public USPTO records.